In the 5/6 nephrectomy rat model of chronic kidney disease in which diabetes does not feature, SGLT2 inhibition with empagliflozin ameliorated glomerular hypertrophy, glomerulosclerosis and interstitial fibrosis as effectively as inhibition of the renin angiotensin system with telmisartan (43). Here, SLC5A2 is linked to chronic kidney disease.